Search

Your search keyword '"Bentz, Tricia"' showing total 12 results
Start Over Author "Bentz, Tricia"
12 results on '"Bentz, Tricia"'

1. Quantifying the Impact of the COVID-19 Pandemic on Cancer Center Clinical Trial Operations

Author

George, Thomas J, primary, Lin, Tara L, additional, Adrales Bentz, Tricia, additional, Grant, Stefan, additional, Houston, Collette M, additional, Nashawati, Melissa A, additional, Pappu, Bhanu, additional, Peck, Helen, additional, Zafirovski, Alex, additional, Kerstann, Kimberly, additional, LoRusso, Patricia, additional, Schnatterly, Anne, additional, Hofacker, Janie, additional, Cameron, Kendra, additional, Honeycutt, Hailey, additional, and Werner, Theresa L, additional

Published
2023
Full Text
View/download PDF

3. Clinical Trial Metrics: The Complexity of Conducting Clinical Trials in North American Cancer Centers

Author

Lee, Carrie, primary, Werner, Theresa L., additional, Deal, Allison M., additional, Krise-Confair, Cassandra J., additional, Bentz, Tricia Adrales, additional, Cummings, Theresa M., additional, Grant, Stefan C., additional, Lee, Ashley Baker, additional, Moehle, Jessica, additional, Moffett, Kristie, additional, Peck, Helen, additional, Williamson, Stephen, additional, Zafirovski, Aleksandar, additional, Shaw, Kate, additional, and Hofacker, Janie K., additional

Published
2021
Full Text
View/download PDF

4. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma

Author

Thomas, Melanie B., primary, Garrett-Mayer, Elizabeth, additional, Anis, Munazza, additional, Anderton, Kate, additional, Bentz, Tricia, additional, Edwards, Andie, additional, Brisendine, Alan, additional, Weiss, Geoffrey, additional, Siegel, Abby B., additional, Bendell, Johanna, additional, Baron, Ari, additional, Duddalwar, Vinay, additional, and El-Khoueiry, Anthony, additional

Published
2018
Full Text
View/download PDF

5. A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors

Author

Britten, Carolyn D., primary, Garrett-Mayer, Elizabeth, additional, Chin, Steven H., additional, Shirai, Keisuke, additional, Ogretmen, Besim, additional, Bentz, Tricia A., additional, Brisendine, Alan, additional, Anderton, Kate, additional, Cusack, Susan L., additional, Maines, Lynn W., additional, Zhuang, Yan, additional, Smith, Charles D., additional, and Thomas, Melanie B., additional

Published
2017
Full Text
View/download PDF

6. A randomized phase II open label multi-institution study of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) in the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC).

Author

Thomas, Melanie B., primary, Garrett-Mayer, Elizabeth, additional, Anis, Munazza, additional, Anderton, Kate Robertson, additional, Bentz, Tricia A, additional, Adelman, Andie Ray, additional, Brisendine, Alan, additional, Duddalwar, Vinay, additional, Weiss, Geoffrey R., additional, Siegel, Abby B., additional, Bendell, Johanna C., additional, Baron, Ari David, additional, and El-Khoueiry, Anthony B., additional

Published
2015
Full Text
View/download PDF

11. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Author

Costa, Luciano J., Fanning, Suzanne R., Stephenson, Joe, Afrin, Lawrence B., Kistner-Griffin, Emily, Bentz, Tricia A., and Stuart, Robert K.

Subjects
CHRONIC lymphocytic leukemia treatment, CANCER relapse, CD20 antigen, ANTIBODY-dependent cell cytotoxicity, CLINICAL trials, CANCER treatment
Abstract

Ofatumumab is a fully human anti-CD20 monoclonal antibody with enhanced antibody dependent and complement dependent cytotoxicity. Lenalidomide induces T cell and natural killer (NK) cell activation and in vitro enhances clearance of chronic lymphocytic leukemia (CLL) cells by monoclonal antibodies. We performed a multi-center, phase 2 trial of sequential treatment with ofatumumab and lenalidomide in patients with advanced, relapsed and refractory (R/R) CLL, consisting of ofatumumab 2000 mg intravenously on day 1 and lenalidomide 10 mg on days 8-28, for up to six cycles. Twenty-one subjects were included with median age of 63 years and two prior lines of therapy. The overall response rate was 47.6% and 23.8% had stable disease. Median overall survival was 21.5 months. Neutropenia and thrombocytopenia were the most frequent adverse events. Tumor flare reaction occurred in 43% of subjects. Intracycle sequential ofatumumab plus lenalidomide is active in high-risk R/R CLL and well tolerated except for frequent cytopenias. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results